Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction results from the DAPA-HF trial

• Kosiborod M.N.
• Jhund P.S.
• Docherty K.F.
• Diez M.
• Petrie M.C.
• Verma S.
• Nicolau J.C.
• Merkely B.
• Kitakaze M.
• DeMets D.L.
• Inzucchi S.E.
• Kober L.
• Martinez F.A.
• Ponikowski P.
• Sabatine M.S.
• Solomon S.D.
• Bengtsson O.
• Lindholm D.
• Niklasson A.
• Sjostrand M.
• Langkilde A.M.
• John J.V. McMurray

Abstract

Background. Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ).

Methods. KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical summary score, and overall summary score. Responder analyses were performed to compare proportions of dapagliflozin versus placebo-treated patients with clinically meaningful changes in KCCQ at 8 months.

Results. A total of 4443 patients had available KCCQ at baseline [median KCCQTSS, 77.1 (interquartile range, 58.391.7)]. The effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening heart failure were consistent across the range of KCCQ-TSS: lowest to highest tertile: hazard ratio 0.70; 95% CI 0.57-0.86; hazard ratio 0.77; 95% CI 0.61-0.98; hazard ratio 0.62; 95% CI 0.46-0.83; p for heterogeneity=0.52. Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months (2.8, 2.5 and 2.3 points higher versus placebo; p<0.0001 for all). Fewer patients treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio 0.84; 95% CI 0.78-0.90; p<0.0001); and more patients had at least small, moderate, and large improvements (odds ratio 1.15; 95% CI, 1.08-1.23; odds ratio 1.15; 95% CI, 1.08-1.22; odds ratio 1.14; 95% CI 1.07-1.22; number needed to treat = 14, 15, and 18, respectively; p<0.0001 for all; results consistent for KCCQ clinical summary score and overall summary score).

Conclusions. Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing at least small, moderate, and large improvements in health status; these effects were clinically important.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03036124.

Keywords:health status, heart failure, outcome, sodium-glucose, transporter 2 inhibitors

REFERENCES

1. Bui A.L., Horwich T.B., Fonarow G.C. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011; 8: 30-41. DOI: https://doi.org/10.1038/nrcardio.2010.165

2. Reddy P., Dunn A.B. The effect of beta-blockers on health-related quality of life in patients with heart failure. Pharmacotherapy. 2000; 20: 679-89. DOI: https://doi.org/10.1592/phco.20.7.679.35178

3. Lewis E.F., Johnson P.A., Johnson W., Collins C., Griffin L., Stevenson L.W. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001; 20: 1016-24. DOI: https://doi.org/10.1016/s1053-2498(01)00298-4

4. Tsevat J., Weeks J.C., Guadagnoli E., Tosteson A.N., Mangi-one C.M., Pliskin J.S., et al. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med. 1994; 9: 576-82. DOI: https://doi.org/10.1007/bf02599287

5. US-FDA. Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatmentheart-failure-endpoints-drug-development-guidance-industry (date of access September 29, 2019)

6. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Kober L.,Kosiborod M.N., Martinez F.A., et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008. DOI: https://doi.org/10.1056/NEJMoa1911303

7. AstraZeneca. AstraZeneca Clinical Trials - Disclosure Commitment. URL: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure(date of access October 29, 2019)

8. McMurray J.J.V., DeMets D.L., Inzucchi S.E., Kober L.,Kosiborod M.N., Langkilde A.M., et al.; DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019; 21: 1402-11. DOI: https://doi.org/10.1002/ejhf.1548

9. McMurray J.J.V., DeMets D.L., Inzucchi S.E., Kober L., Kosiborod M.N., Langkilde A.M., et al.; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019; 21: 665-75. DOI: https://doi.org/10.1002/ejhf.1432

10. Green C.P., Porter C.B., Bresnahan D.R., Spertus J.A. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35: 1245-55. DOI: https://doi.org/10.1016/s0735-1097(00)00531-3

11. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985; 4: 8790. DOI: https://doi.org/10.1002/sim.4780040112

12. Spertus J., Peterson E., Conard M.W., Heidenreich P.A., Krumholz H.M., Jones P., et al.; Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005; 150: 707-15. DOI: https://doi.org/10.1016/j.ahj.2004.12.010

13. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001; 22: 102-10. DOI: https://doi.org/10.1016/s0197–2456(00)00134–3

14. Dewan P., Jhund P.S., Shen L., Petrie M.C., Abraham W.T., Atif Ali M., et al. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019; 21: 577-87. DOI: https://doi.org/10.1002/ejhf.1347

15. Nassif M.E., Windsor S.L., Tang F., Khariton Y., Husain M., Inzucchi S.E., et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF Trial. Circulation. 2019; 140: 1463-76. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042929

16. Ekman I., Chassany O., Komajda M., Bohm M., Borer J.S., Ford I., et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011; 32: 2395-404. DOI: https://doi.org/10.1093/eurheartj/ehr343

17. Lewis E.F., Claggett B.L., McMurray J.J.V., Packer M.,Lefkowitz M.P., Rouleau J.L., et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017; 10: e003430.DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430

18. Flynn K.E., Pina I.L., Whellan D.J., Lin L., Blumenthal J.A., Ellis S.J., et al.; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301: 1451-9. DOI: https://doi.org/10.1001/jama.2009.457

19. Veazie P.J., Noyes K., Li Q., Hall W.J., Buttaccio A., Thevenet-Morrison K., et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol. 2012; 60: 1940-4. DOI: https://doi.org/10.1016/j.jacc.2012.06.054

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)